UK markets open in 2 hours 39 minutes

BioMarin Pharmaceutical Inc. (BMRN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
91.20-0.86 (-0.93%)
At close: 04:00PM EDT
87.99 -3.21 (-3.52%)
After hours: 07:23PM EDT

BioMarin Pharmaceutical Inc.

770 Lindaro Street
San Rafael, CA 94901
United States
415 506 6700

Full-time employees3,401

Key executives

NameTitlePayExercisedYear born
Mr. Alexander HardyPresident, CEO & Director1.72MN/A1969
Mr. Brian R. MuellerCFO & Executive VP1.07M2.47M1974
Dr. C. Greg Guyer Ph.D.Executive VP & Chief Technical Officer1.11MN/A1962
Mr. Jeffrey Robert AjerExecutive VP & Chief Commercial Officer1.1MN/A1962
Dr. Henry J. Fuchs M.D., Ph.D.President of Worldwide Research & Development1.41MN/A1958
Ms. Erin BurkhartGroup VP & Chief Accounting OfficerN/AN/A1979
Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentN/AN/AN/A
Traci McCartyGroup Vice President of Investor RelationsN/AN/AN/A
Mr. George Eric DavisExecutive VP, Chief Legal Officer, General Counsel & Secretary1.23M2.11M1971
Ms. Humaira SerajuddinSenior VP & Chief Marketing OfficerN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Corporate governance

BioMarin Pharmaceutical Inc.’s ISS governance QualityScore as of 1 April 2024 is 3. The pillar scores are Audit: 1; Board: 3; Shareholder rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.